AmpliPhi Biosciences has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 14, 2017 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that the company will make a presentation at the following upcoming event (Press release, Arrowhead Research Corporation, NOV 14, 2017, View Source [SID1234522035]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

29th Annual Piper Jaffray Healthcare Conference – New York, November 28-29, 2017

November 28, 9:30 a.m. EST – Christopher Anzalone Ph.D., Arrowhead president and chief executive officer will participate in a fireside chat presentation.

A webcast of the event may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

On November 14, 2017 NewLink Genetics Corporation (NASDAQ:NLNK) reported the appointment of Eugene P. Kennedy, M.D., FACS, to the role of Chief Medical Officer. He will be responsible for leading all clinical development, medical affairs and related functions. Dr. Kennedy’s previous role at NewLink Genetics was Vice President of Clinical and Medical Affairs (Press release, NewLink Genetics, NOV 14, 2017, View Source [SID1234522068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Gene’s considerable experience in clinical trial design and implementation has made him an invaluable team member at NewLink," said Charles J. Link, Jr., MD, Chairman, Chief Executive Officer and Chief Scientific Officer. "We are glad he has taken on this new responsibility and know he will continue to contribute the critical expertise we need as we commence with enrollment of our pivotal trial for patients with advanced melanoma."

Dr. Kennedy joined NewLink in 2014 from Thomas Jefferson University in Philadelphia, PA where he served as Associate Professor of Surgery and held leadership positions as Chief of the Section of Pancreaticobiliary Surgery and Co-Director of the Jefferson Pancreas, Biliary, and Related Cancers Center. Previously, Dr. Kennedy has held faculty positions at the Johns Hopkins Hospital in Baltimore, MD and the Louisiana State University School of Medicine in New Orleans, LA. Dr. Kennedy obtained his undergraduate education at the University of Virginia and received his medical degree from the Medical College of Virginia. He completed a residency and fellowship in Surgery and Surgical Oncology as well as a research fellowship in tumor immunology at the Johns Hopkins Hospital.

On November 14, 2017 Tusk Therapeutics an immuno-oncology company with a focus on harnessing the power of the immune system to fight cancer through the development of novel immune modulating therapeutics, reported that it has been awarded a £2.5 million grant from Innovate UK (Press release, Tusk Therapeutics, NOV 14, 2017, View Source [SID1234522144]). The grant will be used to accelerate the development of its novel and strongly differentiated anti-CD38 monoclonal antibody as a cancer immunotherapy.
Tusk’s anti-CD38 antibody has the potential to significantly broaden the efficacious utility of monoclonal antibodies targeting the CD38 receptor, extending the current application beyond haematological tumours (e.g. Multiple Myeloma) to solid tumours. Tusk’s antibody’s novel mode of action aims to modulate the tumour microenvironment to allow the body’s immune system to generate a potent anti-tumour response.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The grant will facilitate the completion of preclinical activities for its anti-CD38 antibody program and to conduct a Phase I trial and builds on Tusk’s preclinical research and recent novel insights into CD38 biology.

Luc Dochez, Chief Executive Officer of Tusk Therapeutics, commented: "We thank Innovate UK for supporting us with this grant which we believe is a great endorsement of the work currently being undertaken at Tusk. This grant will allow us to continue to accelerate the development of our novel CD38 programme. Tusk has established a growing, diversified pipeline of antibodies against a selection of both novel and validated targets that we believe have the potential to complement and improve upon current and emerging immune-oncology therapies. The UK is ideally placed as a hub for life science companies. Access to funding and support from industry bodies, such as Innovate UK, is invaluable for companies at our stage of development and is one of the reasons why Tusk, as a European company, has chosen to base itself in the UK."

TapImmune has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, TapImmune, 2017, NOV 14, 2017, View Source [SID1234522072]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!